Veristat delivers integrated marketing application (NDA, BLA, MAA, NDS, etc) preparation expertise with a track record of success and achievement of seemingly impossible deadlines. Our success lies in our ability to navigate operationally complex submissions, overcome data analysis challenges, and streamline the medical writing process with an integrated team focused on creativity, flexibility, and quality.
We provide strategic consulting, biostatistical and programming support, CDISC compliant data standardization, and medical writing services to help you prepare and defend your regulatory submissions. We advise on overall regulatory submission strategy and assist with developing the overall project plan and timelines. We know how to work collaboratively with other third parties to bring all aspects of a submission together.
Our teams are highly skilled and experienced in supporting the development of the following documents and analyses:
Whether you are looking for help preparing your IND, BLA or CTA or your marketing application for (e.g. NDA, MAA, NDS, jNDA) approval - Contact us or explore ore of our insightful perspectives and impactful outcomes:
Veristat has been instrumental in the production of over 75 marketing applications that have led to 50 approvals so far. Our teams have represented pharmaceutical and biotechnology companies in direct regulatory interaction with the US FDA, Health Canada, European Medicines Agency (EMA), Korea FDA and Japan FDA. We have participated in on-site meetings at regulatory agencies and acted as statistical and clinical experts for advisory panel meetings, including acting as the client statistical representative for many of these panels.
Our senior consultants have over twenty-five years of experience guiding companies through the regulatory submission process. We bring together expert regulatory consultants, biostatisticians, medical writers, data standards professionals and statistical programmers who work collaboratively to help our clients prepare their regulatory dossiers for submission and continue to support them throughout the agency review process.
